TriSalus Life Sciences, Inc.
TLSI
$4.19
$0.112.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.51% | -350.65% | -91.32% | 21.44% | 71.64% |
| Total Depreciation and Amortization | -34.72% | -10.44% | -14.95% | -1.71% | -0.52% |
| Total Amortization of Deferred Charges | 58.43% | 64.67% | -3.75% | -- | -- |
| Total Other Non-Cash Items | 107.44% | 175.78% | 160.99% | 46.20% | -84.07% |
| Change in Net Operating Assets | -213.49% | 175.71% | 78.24% | 431.06% | -88.03% |
| Cash from Operations | 56.47% | 65.81% | 45.46% | 58.60% | 37.81% |
| Capital Expenditure | 18.00% | -27.81% | 255.00% | -1,042.42% | 86.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 18.00% | -4.14% | 255.00% | -981.82% | 86.56% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | 84.21% | 72.73% | 95.24% | -222.73% | 13.64% |
| Issuance of Common Stock | -90.71% | -98.49% | 517.33% | -91.14% | 3,444.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 40.26% | -- | 100.00% |
| Cash from Financing | -90.75% | -98.59% | -20.30% | 209.92% | 6,862.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.64% | 26.77% | 7.83% | 157.32% | 70.93% |